The independent source for health policy research, polling, and news.
441 - 460 of 1,305 Results
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But itās āa far cryā from what other nations do to rein in drug prices, and polls show most voters demand more protection.
The number of pharmacies dispensing 340B discounted drugs soared to more than 31,000 this year. Drugmakers struck back by halting some discounts. Hospitals say they are losing millions of dollars ā and cutting back services to patients ā as a result.
More than 1,000 independent rural pharmacies have closed since 2003, leaving 630 communities with no retail drugstore. As 41 million people stuck in pharmacy deserts make do, the remaining drugstores struggle to survive.
Congress is making slow progress toward completing its ambitious social spending bill, although its Thanksgiving deadline looks optimistic. Meanwhile, a new survey finds the average cost of an employer-provided family plan has risen to more than $22,000. Thatās about the cost of a new Toyota Corolla. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHNās Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Rebecca Love, a nurse academic and entrepreneur, about the impending crisis in nursing.
Kids who need a hormone-blocking drug to delay puberty have lost an off-label option. The nearly identical drug the company still sells costs eight times more.
A West Virginia pharmacy cleared a Drug Enforcement Administration investigation. But it shut down anyway, highlighting how the agencyās policies reduce the availability of buprenorphine, an important tool for recovery from opioid addiction.
A last-minute agreement among lawmakers restored a provision seeking to hold down rising costs of prescription medicines. Although details on which drugs will be targeted remain sketchy, the legislation would help patients buying insulin and cap Medicare beneficiariesā out-of-pocket drug costs at $2,000 a year.
Democratic negotiators on Capitol Hill appear to be nearing a compromise on President Joe Bidenās social spending agenda, spurred partly by Democratic losses on Election Day in Virginia. Meanwhile, the Supreme Court hints it might allow abortion providers to sue Texas over its restrictive new ban. But the relief, if it comes, could be short-lived if the court uses a second case, challenging a law in Mississippi, to weaken or overturn Roe v. Wade. Alice Miranda Ollstein of Politico, Margot Sanger-Katz of The New York Times and Mary Ellen McIntire of CQ Roll Call join KHNās Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHNās Rae Ellen Bichell, who reported and wrote the latest KHN-NPR āBill of the Monthā feature about an emergency bill for a nonemergency birth.
Reports of waning effectiveness and mixed messages about booster shots fuel the politicization of vaccination.
A federal allocation plan meant to ensure equitable distribution of powerful monoclonal antibody treatments for high-risk patients fails to prioritize nursing home residents, a population that remains particularly vulnerable even after vaccination.
President Joe Biden unveiled a compromise āBuild Back Betterā framework shortly before taking off for key meetings in Europe, but itās unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the partyās health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHNās Julie Rovner to discuss these issues and more.
With an eye to shutting down Medicare drug price negotiations, drug companies and their lobbying groups gave roughly $1.6 million in the first six months of 2021, with Democrats edging closer than they have in a decade to Republicansā total haul.
KHN teamed up with Hulu for a discussion of America's opioid crisis, following the Oct. 13 premiere of the online streaming serviceās new series āDopesick.ā
But Americans generally have little confidence that the White House or Congress will recommend the right thing, a new poll shows.
Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.
The condition can be an early signal of Alzheimerās disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Hereās a collection of their appearances.
At least three promising antiviral treatments for covid-19 are being tested in clinical trials, with results expected as soon as late fall or winter.
Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Bidenās entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHNās Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.
Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree ā but they are cautious about changing the treatment regimen of patients doing well.
Ā© 2026 KFF